Abstracts tagged "Outcome measures"

Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: 0281 • ACR Convergence 2022
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
Maya Buch¹, BERNARD COMBE², Jose A Gomez-Puerta³, Roberto Felice Caporali⁴, jacques-eric gottenberg⁵, Paul Van Hoek⁶, Vijay Rajendran⁷, Pieter-Jan Stiers⁶, Katrien Van Beneden⁶, Daniel Aletaha⁸, Gerd Burmester⁹, Rene Westhovens¹⁰ and Yoshiya Tanaka¹¹, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Montpellier University, Montpellier, France, ³Hospital Clínic de Barcelona, Barcelona, Spain, ⁴University of Milan, Milano, Italy, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos NV, Gent, Belgium, ⁸Medical University Vienna, Wien, Austria, ⁹Charité University Medicine Berlin, Berlin, Germany, ¹⁰University Hospitals Leuven, Leuven, Belgium, ¹¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for the treatment of moderate to severe active RA.1 It was previously reported that…
Abstract Number: 0650 • ACR Convergence 2022
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
Shudan Wang¹, Masako Suzuki², Daming Shao³, Muhammad Hamza Bukhari⁴, Brianna Lally⁵, Michael Belmont⁶, Jennifer Aguilan², Simone Sidoli², Anna Broder⁷ and J. Michelle Kahlenberg⁸, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Norwalk Hospital/Yale University, Norkwalk, VA, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
Abstract Number: 1064 • ACR Convergence 2022
Test-retest Reliability for the Mawdsley Calcinosis Questionnaire for the Measurement of Calcinosis Burden in Patients with Systemic Sclerosis
Antonia Valenzuela¹, Anne-Marie Russell², Lorinda Chung³, Kelly Jensen⁴ and Lesley Ann Saketkoo⁵, ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²University of Exeter, Exeter, United Kingdom, ³Stanford University, Stanford, CA, ⁴University of Colorado, Bellevue, WA, ⁵University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA
Background/Purpose: Calcinosis cutis is a debilitating manifestation in systemic sclerosis (SSc) responsible for a high burden of disability and hand dysfunction, contributing as much as…
Abstract Number: 1367 • ACR Convergence 2022
Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Brian Feldman⁷, Jordi Anton⁸, Maria Katsicas⁹, Valda Stanevica¹⁰, FLAVIO SZTAJNBOK¹¹, Simone Appenzeller¹², Tadey Avcin¹³, Mikhail Kostik¹⁴, Edoardo Marrani¹⁵, Walter Alberto Sifuentes-Giraldo¹⁶, Sindu Johnson¹⁷, Raju Khubchandani¹⁸, Dana Nemcova¹⁹, Maria José Santos²⁰, Cristina Battagliotti²¹, Lillemor Berntson²², Blanca Bica²³, Jürgen Brunner²³, Rolando Cimaz²⁴, Despina Eleftheriou²⁵, Liora Harel²⁶, Gerd Horneff²⁷, Mahesh Janarthanan²⁸, Tilmann Kallinich²⁹, Kirsten Minden³⁰, Anjali Patwardhan³¹, Dieneke Schonenberg-Meinema³², Vanessa Smith³³ and Nicola Helmus³⁴, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ⁴Cerrahpaşa Medical School, Istanbul University, Istanbul, Turkey, ⁵Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ⁶Universidad Federal São Paulo, São Paulo, Brazil, ⁷Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ⁹Hospital Garrahan, Buenos Aires, Argentina, ¹⁰Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹¹UFRJ/UERJ, São Paulo, Brazil, ¹²Unicamp, Campinas, São Paulo, Brazil, ¹³University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁴Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁵University of Florence, Firenze, Italy, ¹⁶Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸SRCC Children's Hospital, Mumbai, India, ¹⁹Charles University, Prague, Czech Republic, ²⁰Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ²¹Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²²Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²³UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ²⁴University of Milano, Milano, Italy, ²⁵Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ²⁶Schneider Children's Medical center, Tel Aviv University, Nettnja, Israel, ²⁷Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁸SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ²⁹Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ³⁰Charité Universitätsmedizin Berlin, Berlin, Germany, ³¹University of Missouri, Columbia, MO, ³²Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ³³Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ³⁴Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1779 • ACR Convergence 2022
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao², Jessica Williams², S. Sam Lim¹ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic may have a sustained impact on systemic lupus erythematosus (SLE) patients in multiple ways. In a large predominantly Black SLE cohort,…
Abstract Number: 2055 • ACR Convergence 2022
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Alfredo Aguirre¹, Mimi Kim², Kosalaram Goteti³, Ying Li³, Amy Kao⁴, Nathalie Franchimont⁵, George Kong⁵, Catherine Barbey⁶, Qing Zuraw⁷, Robert Gordon⁷, David Manner⁸, Maria Silk⁹, Teodora Staeva¹⁰, Hoang Nguyen¹¹, Richard Furie¹², Matthew Linnik¹³ and Maria Dall'Era¹⁴, ¹University of California, San Francisco, San Francisco, CA, ²Albert Einstein College of Medicine, Larchmont, NY, ³EMD Serono, Boston, MA, ⁴EMD Serono, Billerica, MA, ⁵Biogen, Cambridge, MA, ⁶Biogen, Baar, Switzerland, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Carmel, IN, ¹⁰Lupus Research Alliance, New York, NY, ¹¹Lupus Research Alliance, Houston, TX, ¹²Northwell Health, Great Neck, NY, ¹³Eli Lilly and Company, San Diego, CA, ¹⁴University of California, Division of Rheumatology, San Francisco, CA
Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…
Abstract Number: 0065 • ACR Convergence 2022
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Tarun Sharma¹, paul lebovitz¹, chetan rajput², Lori Mcaninch³, ellen Kraemer³, izabela Stanescu³, adam dore¹, joseph ahearn³ and Susan Manzi⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, ³Allegheny Health Network, Pittsburgh, ⁴Allegheny Health Network, Lupus Center of Excellence, Wexford, PA
Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and…
Abstract Number: 0282 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
Roy Fleischmann¹, Louis Bessette², Jeffrey Sparks³, Stephen Hall⁴, Manish Jain⁵, Adriana Kakehasi⁶, Yanna Song⁷, Sebastian Meerwein⁸, Ryan DeMasi⁷, Jessica Suboticki⁹ and Andrea Rubbert-Roth¹⁰, ¹University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ²Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Emeritus Research and Monash University, Melbourne, Australia, ⁵Great Lakes Clinical Trials, Chicago, IL, ⁶Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁹AbbVie, Inc., Mettawa, IL, ¹⁰Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: For patients with RA who are refractory to biologic disease-modifying antirheumatic drugs (bDMARDs), such as tumor necrosis factor inhibitors (TNFis), optimal disease control is…
Abstract Number: 0710 • ACR Convergence 2022
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Naomi Patel¹, Xiaosong Wang², Xiaoqing Fu³, Yumeko Kawano², Claire Cook³, Kathleen Vanni², Grace Qian², Emily Banasiak², Emily Kowalski², yuqing zhang⁴, Jeffrey Sparks⁵ and Zachary Wallace³, ¹Massachusetts General Hospital, Sale Creek, TN, ²Brigham and Women's Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Some patients with rheumatic disease on DMARDs may be at increased risk of poor response to SARS-CoV-2 vaccines and thus breakthrough COVID-19 infections. We…
Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Vanesa Calvo Río², Javier Loricera³, Nuria Aviles⁴, Juan M Blanco Madrigal⁵, Santos Castañeda⁶, Miguel Angel Gonzalez Gay⁷ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Perpetuo Socorro, Albacete, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 2093 • ACR Convergence 2022
Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.